PT728214E - Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado - Google Patents

Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado

Info

Publication number: PT728214E
Authority: PT; Portugal
Prior art keywords: pct; aav; cell lines; express; additional
Prior art date: 1993-11-09

Application number

PT95900505T

Other languages

English (en)

Inventor

James P Trempe

Qicheng Yang

Original Assignee

Ohio Med College

Targeted Genetics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-09

Filing date

1994-11-03

Publication date

2004-11-30

1994-11-03 Application filed by Ohio Med College, Targeted Genetics Corp filed Critical Ohio Med College

2004-11-30 Publication of PT728214E publication Critical patent/PT728214E/pt

Links

108090000623 proteins and genes Proteins 0.000 title abstract 2
230000029812 viral genome replication Effects 0.000 title 1
239000013607 AAV vector Substances 0.000 abstract 2
238000004806 packaging method and process Methods 0.000 abstract 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 abstract 1
101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 abstract 1
102000003792 Metallothionein Human genes 0.000 abstract 1
108090000157 Metallothionein Proteins 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
101150066583 rep gene Proteins 0.000 abstract 1
230000035897 transcription Effects 0.000 abstract 1
238000013518 transcription Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT95900505T 1993-11-09 1994-11-03 Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado PT728214E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15106593A	1993-11-09	1993-11-09
US27356394A	1994-07-11	1994-07-11

Publications (1)

Publication Number	Publication Date
PT728214E true PT728214E (pt)	2004-11-30

Family

ID=26848297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT95900505T PT728214E (pt)	1993-11-09	1994-11-03	Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado

Country Status (11)

Country	Link
US (1)	US5837484A (pt)
EP (1)	EP0728214B1 (pt)
JP (1)	JP3952312B2 (pt)
AT (1)	ATE272123T1 (pt)
AU (1)	AU678867B2 (pt)
CA (1)	CA2176215C (pt)
DE (1)	DE69433922T2 (pt)
DK (1)	DK0728214T3 (pt)
ES (1)	ES2220923T3 (pt)
PT (1)	PT728214E (pt)
WO (1)	WO1995013392A1 (pt)

Families Citing this family (299)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5436146A (en) *	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
PT733103E (pt) *	1993-11-09	2004-07-30	Targeted Genetics Corp	Criacao de elevados titulos de vectores de aav recombinantes
EP0755454B1 (en)	1994-04-13	2008-02-13	The Rockefeller University	Aav-mediated delivery of dna to cells of the nervous system
US5658785A (en) *	1994-06-06	1997-08-19	Children's Hospital, Inc.	Adeno-associated virus materials and methods
US20020159979A1 (en)	1994-06-06	2002-10-31	Children's Hospital, Inc.	Adeno-associated virus materials and methods
WO1996012010A1 (de) *	1994-10-13	1996-04-25	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Bereitstellung von rep-negativen aav-mutanten und hierfür verwendbare zellen
US5856152A (en) *	1994-10-28	1999-01-05	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV vector and methods of use therefor
US6342390B1 (en)	1994-11-23	2002-01-29	The United States Of America As Represented By The Secretary Of Health And Human Services	Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US6326356B1 (en)	1996-10-18	2001-12-04	Board Of Regents, The University Of Texas System	Suppression of neu overexpression using a mini-E1A gene
US6924128B2 (en)	1994-12-06	2005-08-02	Targeted Genetics Corporation	Packaging cell lines for generation of high titers of recombinant AAV vectors
CA2207927A1 (en) *	1994-12-06	1996-06-13	Targeted Genetics Corporation	Packaging cell lines for generation of high titers of recombinant aav vectors
US5843742A (en) *	1994-12-16	1998-12-01	Avigen Incorporated	Adeno-associated derived vector systems for gene delivery and integration into target cells
US20020103147A1 (en)	1997-09-05	2002-08-01	Hammond H. Kirk	Gene therapy for congestive heart failure
WO1996026742A1 (en)	1995-02-28	1996-09-06	The Regents Of The University Of California	Gene transfer-mediated angiogenesis therapy
US6752987B1 (en)	1995-02-28	2004-06-22	The Regents Of The University Of California	Adenovirus encoding human adenylylcyclase (AC) VI
US6281010B1 (en)	1995-06-05	2001-08-28	The Trustees Of The University Of Pennsylvania	Adenovirus gene therapy vehicle and cell line
US5756283A (en) *	1995-06-05	1998-05-26	The Trustees Of The University Of Pennsylvania	Method for improved production of recombinant adeno-associated viruses for gene therapy
US6093570A (en) *	1995-06-07	2000-07-25	The University Of North Carolina At Chapel Hill	Helper virus-free AAV production
US5622856A (en) *	1995-08-03	1997-04-22	Avigen	High efficiency helper system for AAV vector production
US6001650A (en)	1995-08-03	1999-12-14	Avigen, Inc.	High-efficiency wild-type-free AAV helper functions
EP0842287B1 (en) *	1995-08-03	2004-02-04	Avigen, Inc.	High efficiency helper system for aav vector production
US6162796A (en) *	1995-09-27	2000-12-19	The Rockefeller University	Method for transferring genes to the heart using AAV vectors
US6086913A (en) *	1995-11-01	2000-07-11	University Of British Columbia	Liposomal delivery of AAV vectors
US6004797A (en) *	1995-11-09	1999-12-21	Avigen, Inc.	Adenovirus helper-free recombinant AAV Virion production
US20020193580A1 (en) *	1995-12-15	2002-12-19	Mitchell Lloyd G.	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) *	1995-12-15	2006-04-27	Mitchell Lloyd G	Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) *	1995-12-15	2003-02-06	Mitchell Lloyd G.	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US5952221A (en) *	1996-03-06	1999-09-14	Avigen, Inc.	Adeno-associated virus vectors comprising a first and second nucleic acid sequence
DE19608751B4 (de)	1996-03-06	2006-05-18	Medigene Ag	Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
US6294370B1 (en)	1997-06-24	2001-09-25	Medigene Ag	System for the production of AAV vectors
US6541012B2 (en)	1996-06-24	2003-04-01	Christoph Bogedain	System for the production of AAV vectors
DE19625188A1 (de) *	1996-06-24	1998-01-08	Medigene Gmbh	System zur Herstellung von AAV-Vektoren
JP2001500015A (ja) *	1996-09-06	2001-01-09	トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US5866552A (en) *	1996-09-06	1999-02-02	The Trustees Of The University Of Pennsylvania	Method for expressing a gene in the absence of an immune response
AU722375B2 (en) *	1996-09-06	2000-08-03	Trustees Of The University Of Pennsylvania, The	Methods using cre-lox for production of recombinant adeno-associated viruses
AU742696B2 (en) *	1996-11-18	2002-01-10	Mcgill University	Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
US6541258B2 (en)	1996-12-18	2003-04-01	Targeted Genetics Corporation	AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
AU728220B2 (en) *	1997-04-14	2001-01-04	Cell Genesys, Inc.	Methods for increasing the efficiency of recombinant AAV product
US6251677B1 (en)	1997-08-25	2001-06-26	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV virus and methods of use thereof
US6989264B2 (en)	1997-09-05	2006-01-24	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en)	1997-09-05	2003-05-20	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DK1944362T3 (en)	1997-09-05	2016-01-25	Genzyme Corp	Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer
US6346415B1 (en)	1997-10-21	2002-02-12	Targeted Genetics Corporation	Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US6642051B1 (en) *	1997-10-21	2003-11-04	Targeted Genetics Corporation	Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
IT1297074B1 (it)	1997-11-21	1999-08-03	Angeletti P Ist Richerche Bio	Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
US6953690B1 (en)	1998-03-20	2005-10-11	The Trustees Of The University Of Pennsylvania	Compositions and methods for helper-free production of recombinant adeno-associated viruses
EP1930418B1 (en)	1998-09-04	2015-04-08	Genzyme Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DE69839740D1 (de)	1998-10-22	2008-08-28	Univ Montana	Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis
US6303362B1 (en) *	1998-11-19	2001-10-16	The Board Of Trustees Of The Leland Stanford Junior University	Adenoviral vector and methods for making and using the same
US6387368B1 (en)	1999-02-08	2002-05-14	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV virus and methods of use thereof
US6893865B1 (en) *	1999-04-28	2005-05-17	Targeted Genetics Corporation	Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6793926B1 (en) *	1999-05-27	2004-09-21	Genovo, Inc.	Methods for production of a recombinant adeno-associated virus
EP1180159B1 (en)	1999-05-28	2008-09-03	Targeted Genetics Corporation	Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders
EP1939300A1 (en)	1999-05-28	2008-07-02	Targeted Genetics Corporation	Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
EP1916258B1 (en)	1999-08-09	2014-04-23	Targeted Genetics Corporation	Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
EP2369002A1 (en)	1999-08-09	2011-09-28	Targeted Genetics Corporation	Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
US6627617B1 (en)	1999-10-01	2003-09-30	University Of North Carolina At Chapel Hill	Temperature-sensitive regulation of viral vector production
US7115391B1 (en)	1999-10-01	2006-10-03	Genovo, Inc.	Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
WO2001027303A1 (en) *	1999-10-12	2001-04-19	The University Of North Carolina At Chapel Hill	Adeno-associated virus vectors encoding factor viii and methods of using the same
US6916635B2 (en) *	2000-10-02	2005-07-12	The Research Foundation Of State University Of New York	Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
US20040126774A1 (en) *	2001-01-08	2004-07-01	Mitchell Lioyd G.	Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
US6844192B2 (en)	2001-06-29	2005-01-18	Wake Forest University	Adenovirus E4 protein variants for virus production
EP1427816A4 (en)	2001-09-18	2004-12-01	Clontech Lab Inc	METHOD FOR THE PRODUCTION OF ADENOVIRUS VECTORS, BASED ON A SPECIFIC RECOMBINASE
US7399753B2 (en) *	2002-02-25	2008-07-15	Virxsys Corporation	Trans-splicing mediated photodynamic therapy
US7332276B2 (en)	2002-03-01	2008-02-19	Celltech R&D, Inc.	Methods to increase or decrease bone density
US7094399B2 (en) *	2002-05-08	2006-08-22	Intronn, Inc.	Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses
EP1579004B1 (en) *	2002-10-23	2010-06-16	VIRxSYS Corporation	Screening methods for identification of efficient pre-trans-splicing molecules
JP5433133B2 (ja)	2003-01-22	2014-03-05	デューク・ユニヴァーシティ	リソソームポリペプチドを発現するための改善された構築物
WO2004075861A2 (en) *	2003-02-26	2004-09-10	Children's Hospital, Inc.	Recombinant adeno-associated virus production
US7968334B2 (en) *	2004-01-23	2011-06-28	Virxsys Corporation	Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
AU2005207053A1 (en) *	2004-01-23	2005-08-04	Virxsys Corporation	Expression of ApoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
WO2005070948A1 (en) *	2004-01-23	2005-08-04	Intronn, Inc.	Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
CA2555675A1 (en)	2004-02-10	2005-08-25	Trustees Of Dartmouth College	Nicotinamide riboside kinase compositions and methods for using the same
US20060094110A1 (en) *	2004-07-30	2006-05-04	Mcgarrity Gerard J	Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) *	2004-08-09	2006-06-22	Garcia-Blanco Mariano A	Use of RNA trans-splicing for generation of interfering RNA molecules
US7166963B2 (en) *	2004-09-10	2007-01-23	Axcelis Technologies, Inc.	Electrodeless lamp for emitting ultraviolet and/or vacuum ultraviolet radiation
DE102004047492B4 (de) *	2004-09-23	2006-07-20	Jost-Werke Gmbh & Co. Kg	Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
AU2005326784B2 (en) *	2004-10-08	2012-03-15	Virxsys Corporation	Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
US7871795B2 (en)	2004-10-08	2011-01-18	Virxsys Corporation	Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
ES2569365T3 (es)	2006-11-29	2016-05-10	Nationwide Children's Hospital	Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
US11219696B2 (en)	2008-12-19	2022-01-11	Nationwide Children's Hospital	Delivery of polynucleotides using recombinant AAV9
US9415121B2 (en)	2008-12-19	2016-08-16	Nationwide Children's Hospital	Delivery of MECP2 polynucleotide using recombinant AAV9
JP2012521750A (ja)	2009-03-27	2012-09-20	プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ	肝硬変及び肝線維症の治療のための方法及び組成物
JP5879256B2 (ja)	2009-05-02	2016-03-08	ジェンザイム・コーポレーション	神経変性障害のための遺伝子治療
BR112012010755A2 (pt)	2009-11-05	2015-09-22	Proyecto Biomedicina Cima Sl	constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
EP2643045A4 (en)	2010-11-23	2016-01-13	Presage Biosciences Inc	THERAPEUTIC PROCESSES AND COMPOSITIONS FOR SOLID FORM DELIVERY
WO2012145509A2 (en)	2011-04-19	2012-10-26	The Research Foundation Of State University Of New York	Adeno-associated-virus rep sequences, vectors, and viruses
EP2699673B1 (en)	2011-04-21	2018-09-19	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of myotilin
US10196636B2 (en)	2011-04-21	2019-02-05	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of myotilin
US20130039888A1 (en)	2011-06-08	2013-02-14	Nationwide Children's Hospital Inc.	Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
AU2012286994B2 (en)	2011-07-25	2017-08-10	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of DUX4
WO2013078316A1 (en)	2011-11-23	2013-05-30	Nationwide Children's Hospital, Inc.	Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
US9163259B2 (en)	2012-05-04	2015-10-20	Novartis Ag	Viral vectors for the treatment of retinal dystrophy
BR112015002168A2 (pt)	2012-08-01	2017-11-07	Nationwide Childrens Hospital	liberação intratecal de vírus 9 adeno-associado recombinante
US9539307B2 (en)	2012-09-17	2017-01-10	The Research Institute At Nationwide Children's Hospital	Compositions and methods for treating amyotrophic lateral sclerosis
JP6576904B2 (ja)	2013-04-04	2019-09-18	トラスティーズ・オブ・ダートマス・カレッジ	ＨＩＶ−１プロウイルスＤＮＡのｉｎｖｉｖｏ切除のための組成物及び方法
US9828587B2 (en)	2013-04-08	2017-11-28	University Of Iowa Research Foundation	Chimeric adeno-associated virus/ bocavirus parvovirus vector
EA201990558A3 (ru)	2013-04-20	2021-02-26	Рисёрч Инститъют Эт Нэйшнвайд Чилдрен'С Хоспитал	Доставка нацеленных на экзон 2 полинуклеотидных конструкций u7snrna при помощи рекомбинантного аденоассоциированного вируса
KR20160010526A (ko)	2013-05-15	2016-01-27	리젠츠 오브 더 유니버시티 오브 미네소타	중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
RS63942B1 (sr)	2013-08-27	2023-02-28	Res Inst Nationwide Childrens Hospital	Proizvodi i postupci za lečenje amiotrofične lateralne skleroze
AU2014346987A1 (en)	2013-11-05	2016-06-23	The Research Institute At Nationwide Children's Hospital	Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis
US10047130B2 (en)	2014-03-18	2018-08-14	Washington University	Methods and compositions for red-shifted chromophore substitution for optogenetic applications
EP3180435A4 (en)	2014-08-09	2018-01-17	The Research Institute at Nationwide Children's Hospital	Methods and materials for activating an internal ribosomal entry site in exon 5 of the dmd gene
WO2016057975A2 (en)	2014-10-10	2016-04-14	Research Institute At Nationwide Children's Hospital	Guided injections for aav gene transfer to muscle
US10907130B2 (en)	2014-11-05	2021-02-02	Research Institute At Nationwide Children's Hospital	Methods and materials for producing recombinant viruses in eukaryotic microalgae
WO2016122791A1 (en)	2015-01-30	2016-08-04	The Regents Of The University Of California	Spinal subpial gene delivery system
MA41451A (fr)	2015-02-04	2017-12-12	Univ Washington	Constructions anti-tau
AU2016225179C1 (en)	2015-02-23	2022-11-03	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
CA2986252A1 (en)	2015-05-15	2016-11-24	Regents Of The University Of Minnesota	Adeno-associated virus vector for delivery of iduronate-2-sulfatase to the central nervous system
US10017832B2 (en)	2015-08-25	2018-07-10	Washington University	Compositions and methods for site specific recombination at asymmetric sites
AU2016323575B2 (en)	2015-09-17	2022-10-27	Research Institute At Nationwide Children's Hospital	Methods and materials for GALGT2 gene therapy
CA2998287A1 (en)	2015-09-24	2017-04-20	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
AU2016344609B2 (en)	2015-10-28	2022-05-12	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of duchenne muscular dystrophy
EP3371305A1 (en)	2015-11-06	2018-09-12	Crispr Therapeutics AG	Materials and methods for treatment of glycogen storage disease type 1a
EP3377042A4 (en)	2015-11-16	2019-05-29	The Research Institute at Nationwide Children's Hospital	MATERIALS AND METHOD FOR THE TREATMENT OF TITIN-BASED MYOPATHIES AND OTHER TITINOPATHIES
AU2016364667A1 (en)	2015-12-01	2018-06-21	Crispr Therapeutics Ag	Materials and methods for treatment of Alpha-1 antitrypsin deficiency
MX2018007840A (es)	2015-12-23	2019-05-02	Crispr Therapeutics Ag	Materiales y metodos para el tratamiento de la esclerosis lateral amiotrofica y/o la degeneracion lobar frontotemporal.
US11938193B2 (en)	2016-01-08	2024-03-26	Washington University	Compositions comprising chemerin and methods of use thereof
WO2017134529A1 (en)	2016-02-02	2017-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017139381A1 (en)	2016-02-08	2017-08-17	University Of Iowa Research Foundation	Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
US11066456B2 (en)	2016-02-25	2021-07-20	Washington University	Compositions comprising TREM2 and methods of use thereof
AU2017222653B2 (en)	2016-02-26	2023-06-01	Research Institute At Nationwide Children's Hospital	Recombinant virus products and methods for inducing DUX4 exon skipping
WO2017158422A1 (en)	2016-03-16	2017-09-21	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
KR102489437B1 (ko)	2016-03-28	2023-01-16	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	뉴런 과흥분성 치료를 위한 방법 및 조성물
WO2017173411A1 (en)	2016-04-02	2017-10-05	Research Institute At Nation Wide Children's Hospital	Modified u6 promoter system for tissue specific expression
DK3442602T3 (da)	2016-04-15	2025-05-19	Res Inst Nationwide Childrens Hospital	Adeno-associeret virusvektors frigørelse af mikrodystrofin til behandling af muskeldystrofi
EP4407035A3 (en)	2016-04-15	2024-10-30	Research Institute at Nationwide Children's Hospital	Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
JP6974349B2 (ja)	2016-04-18	2021-12-01	クリスパーセラピューティクスアクチェンゲゼルシャフト	ヘモグロビン異常症の処置のための材料及び方法
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
US11564997B2 (en)	2016-06-29	2023-01-31	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
WO2018002812A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
US11174469B2 (en)	2016-06-29	2021-11-16	Crispr Therapeutics Ag	Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
US11459587B2 (en)	2016-07-06	2022-10-04	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
CA3029132A1 (en)	2016-07-06	2018-01-11	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
IL266639B2 (en)	2016-11-15	2024-06-01	Univ Minnesota	Method for improving neurological function in mpsi and mpsii and other neurological disorders
WO2018094251A1 (en)	2016-11-17	2018-05-24	Kaspar Brian K	Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2
MA46904A (fr)	2016-11-23	2019-10-02	Gritstone Oncology Inc	Administration virale de néo-antigènes
CN118546256A (zh)	2016-12-13	2024-08-27	西雅图儿童医院（Dba西雅图儿童研究所）	在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
WO2018132747A1 (en)	2017-01-13	2018-07-19	University Of Iowa Research Foundation	Bocaparvovirus small noncoding rna and uses thereof
US11781116B2 (en)	2017-02-17	2023-10-10	Lonza Ltd.	Mammalian cells for producing adeno-associated viruses
US20200216857A1 (en)	2017-02-22	2020-07-09	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585807A1 (en)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
EP3585899A1 (en)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
CN119351474A (zh)	2017-02-22	2025-01-24	克里斯珀医疗股份公司	用于基因编辑的组合物和方法
EP3585898A1 (en)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
DK3596222T5 (da)	2017-03-17	2024-09-02	Res Inst Nationwide Childrens Hospital	Adenoassocieret virusvektorfremføring af muskelspecifik mikro-dystrophin til behandling af muskeldystrofi
MA47800A (fr)	2017-03-17	2020-01-22	Univ Newcastle	Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
ES3066629T3 (en)	2017-03-24	2026-05-13	The Univ Court Of The Univ Of Edinburgh	Mecp2 expression cassettes
TW201907937A (zh)	2017-05-08	2019-03-01	美商葛利史東腫瘤科技公司	阿爾法病毒新抗原載體
BR112019023608A2 (pt)	2017-05-12	2020-05-26	Crispr Therapeutics Ag	Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US20200370069A1 (en)	2017-07-08	2020-11-26	Genethon	Treatment of spinal muscular atrophy
SG11201911572YA (en)	2017-07-25	2020-02-27	Oxford Genetics Ltd	Adenoviral vectors
EP3668997A4 (en)	2017-10-02	2021-05-19	Research Institute at Nationwide Children's Hospital	SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE
WO2019079527A1 (en)	2017-10-17	2019-04-25	Casebia Therapeutics Limited Liability Partnership	COMPOSITIONS AND METHODS FOR GENETIC EDITION FOR HEMOPHILIA A
WO2019078916A1 (en)	2017-10-18	2019-04-25	Research Institute At Nationwide Children's Hospital	ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE-SPECIFIC MICRO-DYSTROPHINE TO TREAT MUSCLE DYSTROPHY
IL321310A (en)	2017-10-20	2025-08-01	Res Inst Nationwide Childrens Hospital	Methods and materials for NT-3 gene therapy
EP3701029A1 (en)	2017-10-26	2020-09-02	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
CN120505370A (zh)	2017-11-08	2025-08-19	诺华股份有限公司	制备病毒载体的手段和方法及其用途
US20210032622A1 (en)	2017-11-09	2021-02-04	Crispr Therapeutics Ag	Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
WO2019102381A1 (en)	2017-11-21	2019-05-31	Casebia Therapeutics Llp	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
CN111801417B (zh)	2017-12-14	2024-10-29	克里斯珀医疗股份公司	新的rna-可编程的内切核酸酶系统及其在基因组编辑和其他应用中的用途
EP3728595A1 (en)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
EP3728594A1 (en)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materials and methods for treatment of usher syndrome type 2a
JP7653013B2 (ja)	2018-01-04	2025-03-28	アイコニックセラピューティクスリミテッドライアビリティカンパニー	抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
WO2019140330A1 (en)	2018-01-12	2019-07-18	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting transferrin
AR114350A1 (es)	2018-01-31	2020-08-26	Res Institute At Nationwide ChildrenS Hospital	Terapia genética para la distrofia muscular de cinturas del tipo 2c
US11268077B2 (en)	2018-02-05	2022-03-08	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
WO2019150196A1 (en)	2018-02-05	2019-08-08	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
WO2019161310A1 (en)	2018-02-16	2019-08-22	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting fibrinogen-alpha
JP7550648B2 (ja)	2018-03-19	2024-09-13	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CA3091490A1 (en)	2018-04-27	2019-10-31	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Rapamycin resistant cells
TW202000907A (zh)	2018-05-23	2020-01-01	美商葛利史東腫瘤科技公司	共有抗原
US12228571B2 (en)	2018-06-08	2025-02-18	Novartis Ag	Cell-based assay for measuring drug product potency
GB201809588D0 (en)	2018-06-12	2018-07-25	Univ Bristol	Materials and methods for modulating intraocular and intracranial pressure
US20240254181A1 (en)	2018-06-18	2024-08-01	Research Institute At Nationwide Children's Hospital	Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
BR112020025995A2 (pt)	2018-06-18	2021-03-23	Research Institute At Nationwide Children's Hospital	administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular
WO2020006458A1 (en)	2018-06-29	2020-01-02	Research Institute At Nationwide Children's Hospital	Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
EP3841209A4 (en)	2018-08-22	2023-01-04	Research Institute at Nationwide Children's Hospital	RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITING DYSTROPHIA MYOTONICA PROTEIN KINASE EXPRESSION AND/OR INTERFERING WITH A TRINUCLEOTIDE REPEAT EXPANSION IN THE 3'-UNTRANSLATED REGION OF THE DMPK GENE
EP3844284A1 (en)	2018-08-29	2021-07-07	Research Institute at Nationwide Children's Hospital	Products and methods for inhibition of expression of mutant gars protein
JP7320601B2 (ja)	2018-09-11	2023-08-03	上▲海▼市公共▲衛▼生▲臨▼床中心	広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
CA3116885A1 (en)	2018-10-17	2020-04-23	Crispr Therapeutics Ag	Compositions and methods for delivering transgenes
CA3121191A1 (en)	2018-11-28	2020-06-04	Crispr Therapeutics Ag	Optimized mrna encoding cas9 for use in lnps
AU2019389047A1 (en)	2018-11-30	2021-05-20	Novartis Ag	AAV viral vectors and uses thereof
US20220042045A1 (en)	2018-12-21	2022-02-10	Genethon	Expression cassettes for gene therapy vectors
AU2019419494B2 (en)	2018-12-31	2026-03-26	Research Institute At Nationwide Children's Hospital	DUX4 RNA silencing using RNA targeting CRISPR-Cas13b
JP7691367B2 (ja)	2019-02-04	2025-06-11	リサーチ・インスティチュート・アット・ネーションワイド・チルドレンズ・ホスピタル	Ｃｌｎ３ポリヌクレオチドのアデノ随伴ウイルス送達
BR112021015150A2 (pt)	2019-02-04	2021-09-28	Research Institute At Nationwide Children's Hospital	Entrega de vírus adenoassociado de polinucleotídeo de cln6
EP3923992A1 (en)	2019-02-15	2021-12-22	CRISPR Therapeutics AG	Gene editing for hemophilia a with improved factor viii expression
WO2020174369A2 (en)	2019-02-25	2020-09-03	Novartis Ag	Compositions and methods to treat bietti crystalline dystrophy
SG11202108044YA (en)	2019-02-25	2021-09-29	Novartis Ag	Compositions and methods to treat bietti crystalline dystrophy
CA3131390A1 (en)	2019-02-26	2020-09-03	Research Institute Of Nationwide Children's Hospital	Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
US20220145274A1 (en)	2019-03-12	2022-05-12	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020205889A1 (en)	2019-04-01	2020-10-08	Tenaya Therapeutics, Inc.	Adeno-associated virus with engineered capsid
US20220193259A1 (en)	2019-04-15	2022-06-23	Sanford Research	Gene therapy for treating or preventing visual effects in batten disease
PH12021552610A1 (en)	2019-04-15	2022-06-27	Spirovant Sciences Inc	Compositions and methods for treatment of cystic fibrosis
BR112021020706A2 (pt)	2019-04-15	2022-03-15	Spirovant Sciences Inc	Métodos e composições para expressão de transgene
WO2020225606A1 (en)	2019-05-08	2020-11-12	Crispr Therapeutics Ag	Crispr/cas all-in-two vector systems for treatment of dmd
CA3141020A1 (en)	2019-05-17	2020-11-26	Research Institute At Nationwide Children's Hospital	Optimized gene therapy targeting retinal cells
MX2021014525A (es)	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.
MA56393A (fr)	2019-06-28	2022-05-04	Bayer Healthcare Llc	Matériels et méthodes de régulation de l'édition de gènes
AU2020319168B2 (en)	2019-07-25	2024-02-29	Novartis Ag	Regulatable expression systems
EP4488287A3 (en)	2019-08-21	2025-03-05	Research Institute at Nationwide Children's Hospital	Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
US20230416776A1 (en)	2019-10-08	2023-12-28	Regents Of The University Of Minnesota	Crispr-mediated human genome editing with vectors
WO2021077115A1 (en)	2019-10-18	2021-04-22	Research Institute At Nationwide Children's Hospital	Gene therapy targeting cochlear cells
WO2021077101A1 (en)	2019-10-18	2021-04-22	Research Institute At Nationwide Children's Hospital	Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene
US20230211018A1 (en)	2019-11-22	2023-07-06	Research Institute At Nationwide Children's Hospital	Materials and methods for treatment of disorders associated with the ighmbp2 gene
IL294072A (en)	2019-12-20	2022-08-01	Res Inst Nationwide Childrens Hospital	Gene therapy is efficient for targeting muscle in muscle diseases
AU2021224186A1 (en)	2020-02-18	2022-09-08	Research Institute At Nationwide Children's Hospital	AAV-mediated targeting of mirna in the treatment of X-linked disorders
CA3173793A1 (en)	2020-04-03	2021-10-07	Andrew Ferguson	Infectious disease antigens and vaccines
EP4135776A1 (en)	2020-04-14	2023-02-22	Genethon	Vectors for the treatment of acid ceramidase deficiency
BR112022025586A2 (pt)	2020-06-15	2023-03-07	Res Inst Nationwide Childrens Hospital	Liberação de vetor de vírus adenoassociado para distrofias musculares
US20230242941A1 (en)	2020-06-30	2023-08-03	Eric Yuen	Methods and compositions for administering recombinant viral vectors
US20230374483A1 (en)	2020-07-08	2023-11-23	Regents Of The University Of Minnesota	Modified hexosaminidase and uses thereof
WO2022018638A1 (en)	2020-07-21	2022-01-27	Crispr Therapeutics Ag	Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
JP2023536148A (ja)	2020-07-30	2023-08-23	シェイプセラピューティクスインク．	Ｒａａｖウイルス粒子の誘導産生のための安定な細胞株
EP4192496A4 (en)	2020-08-06	2025-01-01	Gritstone bio, Inc.	MULTIEPITOP VACCINE CASSETTES
US20230414787A1 (en)	2020-08-27	2023-12-28	University Of Iowa Research Foundation	Gene knock-out for treatment of glaucoma
TW202541851A (zh)	2020-09-08	2025-11-01	美商薩羅塔治療公司	表現γ-肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
JP2023541444A (ja)	2020-09-15	2023-10-02	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	筋ジストロフィー患者における多様なｄｍｄ変異の補正のためのａａｖ媒介性の相同性非依存的標的化組み込み遺伝子編集
JP2023543029A (ja)	2020-09-28	2023-10-12	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	筋ジストロフィーの治療のための製品及び方法
EP4222264A1 (en)	2020-09-30	2023-08-09	CRISPR Therapeutics AG	Materials and methods for treatment of amyotrophic lateral sclerosis
JP7415042B2 (ja)	2020-10-09	2024-01-16	テナヤセラピューティクス，インコーポレイテッド	プラコフィリン２遺伝子治療の方法および組成物
JP2023551279A (ja)	2020-11-30	2023-12-07	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	顔面肩甲上腕筋ジストロフィー（ｆｓｈｄ）を治療するための組成物及び方法
CA3205138A1 (en)	2020-12-17	2022-06-23	Vertex Pharmaceuticals Incorporated	Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
EP4284413A1 (en)	2021-01-27	2023-12-06	Research Institute at Nationwide Children's Hospital	Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
AU2022216260A1 (en)	2021-02-03	2023-08-17	Research Institute At Nationwide Children's Hospital	Compositions and methods for treating disease associated with dux4 overexpression
WO2022170082A1 (en)	2021-02-05	2022-08-11	Regents Of The University Of Minnesota	Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses
WO2022170038A1 (en)	2021-02-05	2022-08-11	Amicus Therapeutics, Inc.	Adeno-associated virus delivery of cln3 polynucleotide
AU2022229489A1 (en)	2021-03-04	2023-08-31	Research Institute At Nationwide Children's Hospital	Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
CN115427561B (zh)	2021-03-09	2024-06-04	辉大(上海)生物科技有限公司	工程化CRISPR/Cas13系统及其用途
CA3216711A1 (en)	2021-04-13	2022-10-20	Research Institute At Nationwide Children's Hospital	Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery
EP4323011A1 (en)	2021-04-15	2024-02-21	Spirovant Sciences, Inc.	Methods and compositions for treatment of cystic fibrosis
US12275941B2 (en)	2021-04-15	2025-04-15	Research Institute At Nationwide Children's Hospital	Products and methods for inhibition of expression of dynamin-1 variants
CA3217491A1 (en)	2021-04-23	2022-10-27	Research Institute At Nationwide Children's Hospital	Products and methods for treating muscular dystrophy
US20240425877A1 (en)	2021-05-07	2024-12-26	Ucl Business Ltd	Abca4 genome editing
MX2023013561A (es)	2021-05-17	2024-02-12	Sarepta Therapeutics Inc	Produccion de vectores de aav recombinantes para tratamiento de distrofia muscular.
EP4108263A3 (en)	2021-06-02	2023-03-22	Research Institute at Nationwide Children's Hospital	Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
EP4101928A1 (en)	2021-06-11	2022-12-14	Bayer AG	Type v rna programmable endonuclease systems
IL308896A (en)	2021-06-11	2024-01-01	Bayer Ag	Type v rna programmable endonuclease systems
WO2023283962A1 (en)	2021-07-16	2023-01-19	Huigene Therapeutics Co., Ltd.	Modified aav capsid for gene therapy and methods thereof
US20240350674A1 (en)	2021-08-11	2024-10-24	Solid Biosciences Inc.	Treatment of muscular dystrophy
EP4144841A1 (en)	2021-09-07	2023-03-08	Bayer AG	Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
US20240398985A1 (en)	2021-09-16	2024-12-05	Novartis Ag	Novel transcription factors
US20240401046A1 (en)	2021-10-07	2024-12-05	Research Institute At Nationwide Children' S Hospital	Products and methods for myelin protein zero silencing and treating cmt1b disease
WO2023060233A1 (en)	2021-10-08	2023-04-13	Amicus Therapeutics, Inc.	Biomarkers for lysosomal storage diseases
US12285497B2 (en)	2021-10-15	2025-04-29	Research Institute At Nationwide Children's Hospital	Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
EP4186919A1 (en)	2021-11-30	2023-05-31	Research Institute at Nationwide Children's Hospital	Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
EP4198048A1 (en)	2021-12-16	2023-06-21	Genethon	Calpain-3 gene transfer increase using modified itr sequences
EP4198047A1 (en)	2021-12-16	2023-06-21	Genethon	Fukutin related protein gene transfer increase using modified itr sequences
EP4198134A1 (en)	2021-12-16	2023-06-21	Genethon	Gamma-sarcoglycan gene transfer increase using modified itr sequences
EP4198046A1 (en)	2021-12-16	2023-06-21	Genethon	Alpha-sarcoglycan gene transfer increase using modified itr sequences
WO2023122669A1 (en)	2021-12-21	2023-06-29	Research Institute At Nationwide Children's Hospital	Materials and methods for the treatment of limb girdle muscular dystrophy
CA3243301A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	NEW SMALL PROGRAMMABLE TYPE V RNA ENDONUCLEASE SYSTEMS
US12037616B2 (en)	2022-03-01	2024-07-16	Crispr Therapeutics Ag	Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
EP4486900A2 (en)	2022-03-03	2025-01-08	Research Institute at Nationwide Children's Hospital	Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
CA3255225A1 (en)	2022-04-04	2023-10-12	The Regents Of The University Of California	COMPOSITIONS AND METHODS OF GENETIC COMPLEMENTATION
TW202404993A (zh)	2022-04-11	2024-02-01	美商特納亞治療股份有限公司	具經工程化蛋白殼之腺相關病毒
JP2025517628A (ja)	2022-05-06	2025-06-10	ノバルティスアーゲー	新規の組換えａａｖｖｐ２融合ポリペプチド
JP2025523399A (ja)	2022-06-08	2025-07-23	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	変異型又は病原性ｋｃｎｑ３発現に関連する疾患又は状態を治療するための生成物及び方法
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
JP2025524569A (ja)	2022-07-06	2025-07-30	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	Ｃｌｎ１ポリヌクレオチドのアデノ随伴ウイルス送達
WO2024035782A1 (en)	2022-08-10	2024-02-15	Aav Gene Therapeutics, Inc.	Aav-mediated intramuscular delivery of insulin
US20260097132A1 (en)	2022-09-23	2026-04-09	Sarepta Therapeutics, Inc.	Recombinant aav vectors for treating muscular dystrophy
AU2023360998A1 (en)	2022-10-11	2025-05-22	Research Institute At Nationwide Children's Hospital	Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
EP4605410A1 (en)	2022-10-19	2025-08-27	Affinia Therapeutics Inc.	Recombinant aavs with improved tropism and specificity
WO2024092171A1 (en)	2022-10-26	2024-05-02	University Of Iowa Research Foundation	Method to deliver large genes using virus and a dna recombination system
EP4608856A1 (en)	2022-10-27	2025-09-03	CARGO Therapeutics, Inc.	Compositions and methods for improved immunotherapies
EP4634376A2 (en)	2022-12-13	2025-10-22	Bayer Aktiengesellschaft	Engineered type v rna programmable endonucleases and their uses
WO2024151982A1 (en)	2023-01-13	2024-07-18	Amicus Therapeutics, Inc.	Gene therapy constructs for the treatment of pompe disease
EP4658796A1 (en)	2023-02-01	2025-12-10	Sarepta Therapeutics, Inc.	Raav production methods
WO2024168276A2 (en)	2023-02-09	2024-08-15	Cargo Therapeutics, Inc.	Compositions and methods for immunotherapies
AU2024256934A1 (en)	2023-04-18	2025-11-06	Research Institute At Nationwide Children's Hospital, Inc.	Gene therapy for treating limb girdle muscular dystrophy r9 and congenital muscular dystrophy 1c
EP4705453A2 (en)	2023-05-02	2026-03-11	Research Institute at Nationwide Children's Hospital	A modular system to convert therapeutic microrna expression cassettes from polymerase iii-based to polymerase ii-based promoters
EP4704919A1 (en)	2023-05-02	2026-03-11	Research Institute at Nationwide Children's Hospital	Treatment of multiple sclerosis using nt-3 gene therapy
EP4705326A1 (en)	2023-05-02	2026-03-11	Research Institute at Nationwide Children's Hospital	Gene therapy for treatment of protein misfolding diseases
EP4713345A2 (en)	2023-05-16	2026-03-25	Affinia Therapeutics Inc.	Recombinant aavs with improved tropism and specificity
IL325133A (en)	2023-06-07	2026-02-01	Res Inst Nationwide Childrens Hospital	Gene therapy for lysosomal acid lipase deficiency (LAL-D)
AU2024305531A1 (en)	2023-06-13	2026-01-22	Research Institute At Nationwide Children's Hospital	Materials and methods for the treatment of neurofibromin 1 mutations and diseases resulting therefrom
US20250027087A1 (en)	2023-07-21	2025-01-23	Crispr Therapeutics Ag	Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
EP4512403A1 (en)	2023-08-22	2025-02-26	Friedrich-Schiller-Universität Jena	Neuropeptide b and w-receptor as a target for treating mood disorders and/or chronic stress
CN121969744A (zh)	2023-10-06	2026-05-01	拜耳公司	工程化v型rna可编程核酸内切酶及其用途
WO2025096498A1 (en)	2023-10-30	2025-05-08	Research Institute At Nationwide Children's Hospital	Compositions and methods for treating diseases or conditions associated with progerin expression
WO2025179121A1 (en)	2024-02-21	2025-08-28	Research Institute At Nationwide Children's Hospital	Exon 17-targeted nucleic acids, compositions, and methods for treatment of dystrophin-based myopathies
WO2025186726A1 (en)	2024-03-05	2025-09-12	Crispr Therapeutics Ag	Modulating expression of agt (angiotensinogen) gene
WO2025188993A2 (en)	2024-03-07	2025-09-12	Research Institute At Nationwide Children's Hospital	Gene therapy for treating gne-related disorders
WO2025194042A1 (en)	2024-03-14	2025-09-18	Affinia Therapeutics Inc.	Plasmid system for production of recombinant adenoassociated virus
WO2025212838A1 (en)	2024-04-03	2025-10-09	Research Institute At Nationwide Children's Hospital	Products and methods for treating diseases or disorders associated with dux4 overexpression
WO2025227063A1 (en)	2024-04-26	2025-10-30	Affinia Therapeutics Inc.	Recombinant aavs with improved tropism and specificity
WO2025226343A1 (en)	2024-04-26	2025-10-30	Research Institute At Nationwide Children's Hospital	Products and methods to inhibit expression of dynamin-1 variants and replace dynamin-1
WO2025235425A1 (en)	2024-05-06	2025-11-13	Research Institute At Nationwide Children's Hospital	Improved proviral plasmids
WO2025235491A1 (en)	2024-05-07	2025-11-13	Affinia Therapeutics Inc.	Recombinant aav for treatment of cardiac diseases
WO2025240690A2 (en)	2024-05-15	2025-11-20	Research Institute At Nationwide Children's Hospital	Products and methods for treating diseases or conditions associated with progerin expression from an aberrant lmna gene
WO2025250909A1 (en)	2024-05-31	2025-12-04	Sarepta Therapeutics, Inc.	Muscle-tropic recombinant aav
WO2026028089A1 (en)	2024-07-29	2026-02-05	Novartis Ag	Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
WO2026094009A1 (en)	2024-11-04	2026-05-07	Insmed Incorporated	Compositions and methods for treating duchenne muscular dystrophy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4797368A (en) *	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en) *	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5141742A (en) *	1986-02-07	1992-08-25	Oncogen	Vaccines against melanoma
AU7906691A (en) *	1990-05-23	1991-12-10	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) *	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
DE4436664A1 (de) *	1994-10-13	1996-07-04	Max Planck Gesellschaft	Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen

1994
- 1994-11-03 AT AT95900505T patent/ATE272123T1/de not_active IP Right Cessation
- 1994-11-03 EP EP95900505A patent/EP0728214B1/en not_active Expired - Lifetime
- 1994-11-03 WO PCT/US1994/012582 patent/WO1995013392A1/en not_active Ceased
- 1994-11-03 PT PT95900505T patent/PT728214E/pt unknown
- 1994-11-03 US US08/362,608 patent/US5837484A/en not_active Expired - Fee Related
- 1994-11-03 ES ES95900505T patent/ES2220923T3/es not_active Expired - Lifetime
- 1994-11-03 JP JP51387495A patent/JP3952312B2/ja not_active Expired - Fee Related
- 1994-11-03 DE DE69433922T patent/DE69433922T2/de not_active Expired - Fee Related
- 1994-11-03 AU AU81309/94A patent/AU678867B2/en not_active Ceased
- 1994-11-03 DK DK95900505T patent/DK0728214T3/da active
- 1994-11-03 CA CA002176215A patent/CA2176215C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0728214B1 (en)	2004-07-28
JPH09510602A (ja)	1997-10-28
WO1995013392A1 (en)	1995-05-18
DK0728214T3 (da)	2004-11-29
JP3952312B2 (ja)	2007-08-01
DE69433922T2 (de)	2005-07-28
CA2176215C (en)	2007-06-26
EP0728214A4 (en)	1997-02-12
US5837484A (en)	1998-11-17
CA2176215A1 (en)	1995-05-18
DE69433922D1 (de)	2004-09-02
ES2220923T3 (es)	2004-12-16
EP0728214A1 (en)	1996-08-28
AU678867B2 (en)	1997-06-12
ATE272123T1 (de)	2004-08-15
AU8130994A (en)	1995-05-29

Publication	Publication Date	Title
EP0728214A4 (en)	1997-02-12	STABLE CELL LINE, ABLE TO EXPRESS THE REPLICATION GENE OF THE ADENO ASSOCIATED VIRUS
MX9709549A (es)	1998-03-31	Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen.
AU1539595A (en)	1995-08-15	Process for preparing recombinant adeno-associated viruses (AAVs), and uses
WO1993024641A3 (en)	1994-05-11	Adeno-associated virus with inverted terminal repeat sequences as promoter
EP0733103A4 (en)	1997-12-17	ACHIEVING HIGH TITERS OF THE RECOMBINANT AAV VECTOR
AU1189195A (en)	1995-06-27	Recombinant protein production in bovine adenovirus expression vector system
CA2120514A1 (en)	1993-04-15	Synthetic dna sequence having enhanced insecticidal activity in maize
DE69535703D1 (de)	2008-03-27	Aav-vermittelte überbringung von dna in zellen des nervensystems
ES2103266T3 (es)	1997-09-16	Procedimiento de dna recombinante y celulas huesped.
EP0706319A4 (en)	1998-04-22	RETROVIRAL VECTORS WITH THE ABILITY TO EXPRESS MULTIMERAL PROTEINS FROM MULTIPLE TRANSLATION INITIATION LOCATIONS
AU5141993A (en)	1994-04-26	Methods and compositions for controlling translation of hcv proteins
HU9202458D0 (en)	1992-10-28	Expressing systems
CA2304105A1 (en)	1999-04-01	Control pod dehiscence or shatter
PT988391E (pt)	2005-05-31	Vectores adenovirais recombinantes compreendendo uma sequencia de splicing
WO1996001317A3 (en)	1996-04-18	Mammalian peroxisome proliferator-activated receptors and uses thereof
WO1994013812A3 (en)	1994-11-10	Novel entomopoxvirus genes, proteins and methods of use thereof
AU6724794A (en)	1995-04-03	GRB3-3 gene, its variants and their uses
AU4835696A (en)	1996-09-11	Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells, therapeutic and vaccine applications.
DE69632201D1 (de)	2004-05-19	Regulierte expression von proteinen in stabil transformierten säugetierzellen
HUP9802587A2 (hu)	1999-02-01	Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
CA2033069A1 (en)	1990-11-20	Saf polypeptide, gene, promoter and use for expression in streptomyces
CA2139430A1 (fr)	1994-01-20	Polypeptides ayant une activite de recepteur serotoninergique (5ht5a), acides nucleiques codant pour ces polypeptides et utilisations
DK0528925T3 (da)	1994-10-24	Klonings- og/eller ekspressionsvektorer, deres fremstilling og anvendelse
GB2318793A (en)	1998-05-06	Mpt83 gene from mycobacterium tuberculosis
AU5110390A (en)	1990-09-13	Cdna coding for placental protein 9 (pp9), the isolation and use thereof